347 related articles for article (PubMed ID: 31175404)
1. Fracture risk following intermission of osteoporosis therapy.
Dennison EM; Cooper C; Kanis JA; Bruyère O; Silverman S; McCloskey E; Abrahamsen B; Prieto-Alhambra D; Ferrari S;
Osteoporos Int; 2019 Sep; 30(9):1733-1743. PubMed ID: 31175404
[TBL] [Abstract][Full Text] [Related]
2. A systematic review and meta-analysis of the effect of bisphosphonate drug holidays on bone mineral density and osteoporotic fracture risk.
Nayak S; Greenspan SL
Osteoporos Int; 2019 Apr; 30(4):705-720. PubMed ID: 30623214
[TBL] [Abstract][Full Text] [Related]
3. Significant bone loss after stopping long-term denosumab treatment: a post FREEDOM study.
Zanchetta MB; Boailchuk J; Massari F; Silveira F; Bogado C; Zanchetta JR
Osteoporos Int; 2018 Jan; 29(1):41-47. PubMed ID: 28975362
[TBL] [Abstract][Full Text] [Related]
4. Screening for the primary prevention of fragility fractures among adults aged 40 years and older in primary care: systematic reviews of the effects and acceptability of screening and treatment, and the accuracy of risk prediction tools.
Gates M; Pillay J; Nuspl M; Wingert A; Vandermeer B; Hartling L
Syst Rev; 2023 Mar; 12(1):51. PubMed ID: 36945065
[TBL] [Abstract][Full Text] [Related]
5. Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation.
Davis S; Simpson E; Hamilton J; James MM; Rawdin A; Wong R; Goka E; Gittoes N; Selby P
Health Technol Assess; 2020 Jun; 24(29):1-314. PubMed ID: 32588816
[TBL] [Abstract][Full Text] [Related]
6. Drug holidays from bisphosphonates and denosumab in postmenopausal osteoporosis: EMAS position statement.
Anagnostis P; Paschou SA; Mintziori G; Ceausu I; Depypere H; Lambrinoudaki I; Mueck A; Pérez-López FR; Rees M; Senturk LM; Simoncini T; Stevenson JC; Stute P; Trémollieres FA; Goulis DG
Maturitas; 2017 Jul; 101():23-30. PubMed ID: 28539165
[TBL] [Abstract][Full Text] [Related]
7. Long-Term Drug Therapy and Drug Discontinuations and Holidays for Osteoporosis Fracture Prevention: A Systematic Review.
Fink HA; MacDonald R; Forte ML; Rosebush CE; Ensrud KE; Schousboe JT; Nelson VA; Ullman K; Butler M; Olson CM; Taylor BC; Brasure M; Wilt TJ
Ann Intern Med; 2019 Jul; 171(1):37-50. PubMed ID: 31009947
[TBL] [Abstract][Full Text] [Related]
8. Postmenopausal Osteoporosis: A Clinical Review.
Watts NB
J Womens Health (Larchmt); 2018 Sep; 27(9):1093-1096. PubMed ID: 29583083
[TBL] [Abstract][Full Text] [Related]
9. Bisphosphonate drug holidays in postmenopausal osteoporosis: effect on clinical fracture risk.
Mignot MA; Taisne N; Legroux I; Cortet B; Paccou J
Osteoporos Int; 2017 Dec; 28(12):3431-3438. PubMed ID: 28875236
[TBL] [Abstract][Full Text] [Related]
10. Three-year denosumab treatment in postmenopausal Japanese women and men with osteoporosis: results from a 1-year open-label extension of the Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT).
Sugimoto T; Matsumoto T; Hosoi T; Miki T; Gorai I; Yoshikawa H; Tanaka Y; Tanaka S; Fukunaga M; Sone T; Nakano T; Ito M; Matsui S; Yoneda T; Takami H; Watanabe K; Osakabe T; Okubo N; Shiraki M; Nakamura T
Osteoporos Int; 2015 Feb; 26(2):765-74. PubMed ID: 25403903
[TBL] [Abstract][Full Text] [Related]
11. The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study.
Papapoulos S; Lippuner K; Roux C; Lin CJ; Kendler DL; Lewiecki EM; Brandi ML; Czerwiński E; Franek E; Lakatos P; Mautalen C; Minisola S; Reginster JY; Jensen S; Daizadeh NS; Wang A; Gavin M; Libanati C; Wagman RB; Bone HG
Osteoporos Int; 2015 Dec; 26(12):2773-83. PubMed ID: 26202488
[TBL] [Abstract][Full Text] [Related]
12. Observations following discontinuation of long-term denosumab therapy.
McClung MR; Wagman RB; Miller PD; Wang A; Lewiecki EM
Osteoporos Int; 2017 May; 28(5):1723-1732. PubMed ID: 28144701
[TBL] [Abstract][Full Text] [Related]
13. Long-term denosumab treatment restores cortical bone loss and reduces fracture risk at the forearm and humerus: analyses from the FREEDOM Extension cross-over group.
Bilezikian JP; Lin CJF; Brown JP; Wang AT; Yin X; Ebeling PR; Fahrleitner-Pammer A; Franek E; Gilchrist N; Miller PD; Simon JA; Valter I; Zerbini CAF; Libanati C; Chines A
Osteoporos Int; 2019 Sep; 30(9):1855-1864. PubMed ID: 31201481
[TBL] [Abstract][Full Text] [Related]
14. Western Osteoporosis Alliance Clinical Practice Series: Evaluating the Balance of Benefits and Risks of Long-Term Osteoporosis Therapies.
Hanley DA; McClung MR; Davison KS; Dian L; Harris ST; Miller PD; Lewiecki EM; Kendler DL;
Am J Med; 2017 Jul; 130(7):862.e1-862.e7. PubMed ID: 28359721
[TBL] [Abstract][Full Text] [Related]
15. Duration of Bisphosphonate Drug Holidays and Associated Fracture Risk.
Curtis JR; Saag KG; Arora T; Wright NC; Yun H; Daigle S; Matthews R; Delzell E
Med Care; 2020 May; 58(5):419-426. PubMed ID: 31985584
[TBL] [Abstract][Full Text] [Related]
16. Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bisphosphonate.
Brown JP; Roux C; Ho PR; Bolognese MA; Hall J; Bone HG; Bonnick S; van den Bergh JP; Ferreira I; Dakin P; Wagman RB; Recknor C
Osteoporos Int; 2014 Jul; 25(7):1953-61. PubMed ID: 24676847
[TBL] [Abstract][Full Text] [Related]
17. Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years.
Ferrari S; Adachi JD; Lippuner K; Zapalowski C; Miller PD; Reginster JY; Törring O; Kendler DL; Daizadeh NS; Wang A; O'Malley CD; Wagman RB; Libanati C; Lewiecki EM
Osteoporos Int; 2015 Dec; 26(12):2763-71. PubMed ID: 26068295
[TBL] [Abstract][Full Text] [Related]
18. Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports.
Aubry-Rozier B; Gonzalez-Rodriguez E; Stoll D; Lamy O
Osteoporos Int; 2016 May; 27(5):1923-5. PubMed ID: 26510845
[TBL] [Abstract][Full Text] [Related]
19. Determinants of change in bone mineral density and fracture risk during bisphosphonate holiday.
Xu LH; Adams-Huet B; Poindexter JR; Maalouf NM
Osteoporos Int; 2016 May; 27(5):1701-8. PubMed ID: 26642963
[TBL] [Abstract][Full Text] [Related]
20. Treatment of post-menopausal osteoporosis: beyond bisphosphonates.
Ishtiaq S; Fogelman I; Hampson G
J Endocrinol Invest; 2015 Jan; 38(1):13-29. PubMed ID: 25194424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
